The Wall Street Journal: Eli Lilly COVID-19 antibody drug shipments paused over variant concerns

U.S. health officials have paused the distribution of two Eli Lilly & Co. Covid-19 monoclonal antibody treatments because of data showing they aren’t effective against virus variants that are becoming increasingly common across the country.